Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMN Stock Forecast 2025-2026
$9.10
Current Price
$19.59M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMN Price Targets
+4,842.4%
To High Target of $449.76
+1,916.2%
To Median Target of $183.47
+733.1%
To Low Target of $75.81
PMN Price Momentum
+19.3%
1 Week Change
-9.0%
1 Month Change
-62.1%
1 Year Change
-61.7%
Year-to-Date Change
-77.1%
From 52W High of $39.75
+45.1%
From 52W Low of $6.27
📊 TOP ANALYST CALLS
Did PMN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProMIS is one of their latest high-conviction picks.
Latest PMN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PMN has a bullish consensus with a median price target of $183.47 (ranging from $75.81 to $449.76). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $9.10, the median forecast implies a 1,916.2% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMN Analyst Ratings
4
Buy
0
Hold
0
Sell
PMN Price Target Range
Low
$75.81
Average
$183.47
High
$449.76
Current: $9.10
Latest PMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 1, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Nov 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $4.00 |
| Nov 18, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $5.00 |
| Jul 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $4.00 |
| May 12, 2025 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
| Apr 1, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $6.00 |
| Feb 26, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $N/A |
| Oct 3, 2023 | BTIG | Thomas Shrader | Buy | Initiates | $8.00 |
ProMIS Neurosciences Inc. (PMN) Competitors
The following stocks are similar to ProMIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PMN
ProMIS Neurosciences
mkt cap
17.03M
ProMIS Neurosciences Inc. (PMN) Financial Data
ProMIS Neurosciences Inc. has a market capitalization of $19.59M with a P/E ratio of 7.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -355.8%.
Valuation Metrics
Market Cap
$19.59M
Enterprise Value
$1.58M
P/E Ratio
7.8x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+78.8%
Current Ratio
1.8x
Debt/Equity
0.0x
ROE
-355.8%
ROA
-85.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProMIS Neurosciences Inc. (PMN) Business Model
About ProMIS Neurosciences Inc.
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
The company utilizes a proprietary technology platform to identify and target misfolded proteins linked to conditions like Alzheimer's and ALS. ProMIS Neurosciences generates revenue by developing precision medicines that address specific unmet medical needs in the neurodegenerative disease space, often through collaborations with academic institutions and strategic partners.
Additional Information
Headquartered in Toronto, Canada, ProMIS Neurosciences is positioned within the biotech sector, emphasizing the importance of targeted therapies in the pharmaceutical and healthcare industries. The company's innovative approach may significantly impact the treatment landscape for debilitating diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Mr. Neil K. Warma M.B.A.
Country
Canada
IPO Year
2022
Website
www.promisneurosciences.comProMIS Neurosciences Inc. (PMN) Latest News & Analysis
Latest News
Quick Summary
PMN310 shows potential to enhance outcomes by selectively targeting oligomers while avoiding monomer and plaque binding, indicating promising therapeutic advantages.
Why It Matters
PMN310's targeted approach may enhance treatment efficacy, impacting future sales projections and stock performance in the biotech sector focused on neurodegenerative diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences (Nasdaq: PMN) CEO Neil Warma will participate in a fireside chat at the Evercore Healthcare Conference on December 2, 2025. A live webcast is available on their website.
Why It Matters
CEO Neil Warma's participation in a major healthcare conference highlights ProMIS's visibility and potential, crucial for attracting investor interest in its Alzheimer's therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences reports positive findings on plasma pTau as a predictor of clinical benefit, supporting its PRECISE-AD trial, with an interim readout planned for Q2 2026.
Why It Matters
ProMIS' findings on plasma pTau as an early predictor enhance the credibility of its trial, potentially increasing its stock value and attracting investor interest in Alzheimer's therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) will implement a one-for-twenty-five reverse stock split of its common shares, effective immediately, as announced on November 24, 2025.
Why It Matters
The reverse stock split indicates a strategic move to boost share price and attract institutional investors, potentially impacting liquidity and market perception of ProMIS Neurosciences.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
29 days ago
Quick Summary
ProMIS Neurosciences' Phase 1b Alzheimer's trial is over 85% enrolled, with cohorts fully enrolled. Interim data expected in Q2 2026, final results in Q4 2026. Financial results for Q3 2025 announced.
Why It Matters
Progress in ProMIS Neurosciences' Alzheimer's trial and upcoming data releases could signal advancements in treatment, impacting stock value and investor confidence in biotech innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
1 month ago
Quick Summary
ProMIS Neurosciences (Nasdaq: PMN) will participate in the Guggenheim Healthcare Innovation Conference on November 10, 2025, with CEO Neil Warma and senior management present for discussions and meetings.
Why It Matters
ProMIS Neurosciences' participation in a major healthcare conference highlights its commitment to engaging with investors and could indicate upcoming developments or partnerships in Alzheimer's research, affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PMN Stock
What is ProMIS Neurosciences Inc.'s (PMN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, ProMIS Neurosciences Inc. (PMN) has a median price target of $183.47. The highest price target is $449.76 and the lowest is $75.81.
Is PMN stock a good investment in 2026?
According to current analyst ratings, PMN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMN stock?
Wall Street analysts predict PMN stock could reach $183.47 in the next 12 months. This represents a 1,916.2% increase from the current price of $9.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProMIS Neurosciences Inc.'s business model?
The company utilizes a proprietary technology platform to identify and target misfolded proteins linked to conditions like Alzheimer's and ALS. ProMIS Neurosciences generates revenue by developing precision medicines that address specific unmet medical needs in the neurodegenerative disease space, often through collaborations with academic institutions and strategic partners.
What is the highest forecasted price for PMN ProMIS Neurosciences Inc.?
The highest price target for PMN is $449.76 from at , which represents a 4,842.4% increase from the current price of $9.10.
What is the lowest forecasted price for PMN ProMIS Neurosciences Inc.?
The lowest price target for PMN is $75.81 from at , which represents a 733.1% increase from the current price of $9.10.
What is the overall PMN consensus from analysts for ProMIS Neurosciences Inc.?
The overall analyst consensus for PMN is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $183.47.
How accurate are PMN stock price projections?
Stock price projections, including those for ProMIS Neurosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 3:50 AM UTC